Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients

C. Rossi, M. Zucchetti, C. Sessa, R. Urso, C. Mangioni, M. D'Incalci

Research output: Contribution to journalArticle

Abstract

Plasma levels of VM26 were assayed by HPLC in six ovarian cancer patients with normal renal and liver function who received the drugs as an initial 1-h IV infusion of 80 mg/m2 followed by a 24-h IV infusion of 120 mg/m2. These doses and infusion rates were chosen on the basis of mean VM26 clearance values found in a previous study, with the aim of reaching plasma steady-state levels of approximately 6 μg/ml in a short time. Plasma steady-state levels of 4-10 μg/ml, close to those predicted theoretically, were in fact attained at 4-9 h during the second, slower infusion. Mean half-lives and clearance values were 8.6±1.1 h and 0.78±0.08 l/h/m2. Six percent of the VM26 dose was recovered as unchanged drug in the urines collected up to 24 h after the end of infusion. The glucuronide of VM26 aglycone (4′-demethylepipodophyllotoxin) was identified in the urine of all patients, in amounts corresponding to about 8% of the drug dose.

Original languageEnglish
Pages (from-to)211-214
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume13
Issue number3
DOIs
Publication statusPublished - Oct 1984

Fingerprint

Pharmacokinetics
Ovarian Neoplasms
Plasmas
Urine
Pharmaceutical Preparations
Glucuronides
Liver
High Pressure Liquid Chromatography
Kidney

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients. / Rossi, C.; Zucchetti, M.; Sessa, C.; Urso, R.; Mangioni, C.; D'Incalci, M.

In: Cancer Chemotherapy and Pharmacology, Vol. 13, No. 3, 10.1984, p. 211-214.

Research output: Contribution to journalArticle

@article{7f6655572c1c464ba7f95f5cc3d1fe66,
title = "Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients",
abstract = "Plasma levels of VM26 were assayed by HPLC in six ovarian cancer patients with normal renal and liver function who received the drugs as an initial 1-h IV infusion of 80 mg/m2 followed by a 24-h IV infusion of 120 mg/m2. These doses and infusion rates were chosen on the basis of mean VM26 clearance values found in a previous study, with the aim of reaching plasma steady-state levels of approximately 6 μg/ml in a short time. Plasma steady-state levels of 4-10 μg/ml, close to those predicted theoretically, were in fact attained at 4-9 h during the second, slower infusion. Mean half-lives and clearance values were 8.6±1.1 h and 0.78±0.08 l/h/m2. Six percent of the VM26 dose was recovered as unchanged drug in the urines collected up to 24 h after the end of infusion. The glucuronide of VM26 aglycone (4′-demethylepipodophyllotoxin) was identified in the urine of all patients, in amounts corresponding to about 8{\%} of the drug dose.",
author = "C. Rossi and M. Zucchetti and C. Sessa and R. Urso and C. Mangioni and M. D'Incalci",
year = "1984",
month = "10",
doi = "10.1007/BF00269031",
language = "English",
volume = "13",
pages = "211--214",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients

AU - Rossi, C.

AU - Zucchetti, M.

AU - Sessa, C.

AU - Urso, R.

AU - Mangioni, C.

AU - D'Incalci, M.

PY - 1984/10

Y1 - 1984/10

N2 - Plasma levels of VM26 were assayed by HPLC in six ovarian cancer patients with normal renal and liver function who received the drugs as an initial 1-h IV infusion of 80 mg/m2 followed by a 24-h IV infusion of 120 mg/m2. These doses and infusion rates were chosen on the basis of mean VM26 clearance values found in a previous study, with the aim of reaching plasma steady-state levels of approximately 6 μg/ml in a short time. Plasma steady-state levels of 4-10 μg/ml, close to those predicted theoretically, were in fact attained at 4-9 h during the second, slower infusion. Mean half-lives and clearance values were 8.6±1.1 h and 0.78±0.08 l/h/m2. Six percent of the VM26 dose was recovered as unchanged drug in the urines collected up to 24 h after the end of infusion. The glucuronide of VM26 aglycone (4′-demethylepipodophyllotoxin) was identified in the urine of all patients, in amounts corresponding to about 8% of the drug dose.

AB - Plasma levels of VM26 were assayed by HPLC in six ovarian cancer patients with normal renal and liver function who received the drugs as an initial 1-h IV infusion of 80 mg/m2 followed by a 24-h IV infusion of 120 mg/m2. These doses and infusion rates were chosen on the basis of mean VM26 clearance values found in a previous study, with the aim of reaching plasma steady-state levels of approximately 6 μg/ml in a short time. Plasma steady-state levels of 4-10 μg/ml, close to those predicted theoretically, were in fact attained at 4-9 h during the second, slower infusion. Mean half-lives and clearance values were 8.6±1.1 h and 0.78±0.08 l/h/m2. Six percent of the VM26 dose was recovered as unchanged drug in the urines collected up to 24 h after the end of infusion. The glucuronide of VM26 aglycone (4′-demethylepipodophyllotoxin) was identified in the urine of all patients, in amounts corresponding to about 8% of the drug dose.

UR - http://www.scopus.com/inward/record.url?scp=0021130598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021130598&partnerID=8YFLogxK

U2 - 10.1007/BF00269031

DO - 10.1007/BF00269031

M3 - Article

C2 - 6488441

AN - SCOPUS:0021130598

VL - 13

SP - 211

EP - 214

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -